非小细胞肺癌的免疫疗法市场:KOL的洞察

本报告提供全球非小细胞肺癌(NSCLC)的免疫疗法市场相关调查，提供市场概要，以及已通过核准治疗方法，开发平台趋势，未来预测等资讯。

目录

摘要整理

现在及未来的治疗流程

调查目的

PD-1/L1及CTLA-4为基础的方案

• 已通过核准/开发平台计划(40)
  • 晚期非小细胞肺癌（Merck &Co.、BMS、罗氏、阿斯特捷利康、再生元、第一三共）
  • III 期不可切除的 NSCLC（Merck &Co.、BMS、AstraZeneca）
  • 早期 NSCLC（Merck &Co.、BMS、Roche、AstraZeneca）
  • ICI 后的设置

抗PD1/VEGF双特异性抗体

• 管道疗法
  • Ibonesimab（SMT112，高峰会）

抗TIGIT单株抗体

• 管道疗法
  • Tilagolumab（RG6058，罗氏）、Vivostrimab（MK-7684，Merck &Co.）、奥西培利单抗（BGB-A1217，百济神州）、Donvanalimab（AB154，Arcus/Gilead）

LAG3 代理

• 管道疗法
  • Eftilagimod alpha（IMP321，Immutep）

未来治疗趋势

• 主要见解摘要

附录

How do KOLs interpret data from Checkmate-816, and how does this now inform the treatment of patients with early-stage resectable NSCLC without EGFR or ALK genomic alterations? Why do oncologists say the KEYNOTE-671 findings for Merck & Co.'s Keytruda will likely impact NSCLC treatment practice? How do experts assess the potential to re-challenge with IO-based therapy? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to KOL Bulletins via the Attachments area.

Table of Contents

Executive summary (9)

Current and future treatment algorithm

Research objectives (2)

PD-1/L1 and CTLA-4-based regimens (40)

• Approved/pipeline programmes (40)
  • Advanced NSCLC (Merck & Co.; BMS; Roche; AstraZeneca; Regeneron; Daiichi Sankyo) (11)
  • Stage III non-resectable NSCLC (Merck & Co.; BMS; AstraZeneca) (6)
  • Early-stage NSCLC (Merck & Co.; BMS; Roche; AstraZeneca) (13)
  • Post-ICI settings (10)

Anti-PD1/VEGF bispecific antibody (7)

• Pipeline therapy (7)
  • Ivonescimab (SMT112; Summit) (7)

Anti-TIGIT monoclonal antibodies (10)

• Pipeline therapies (10)
  • Tiragolumab (RG6058; Roche), vibostolimab (MK-7684; Merck & Co.), ociperlimab (BGB-A1217; BeiGene) and domvanalimab (AB154; Arcus/Gilead) (10)

LAG3 agents (5)

• Pipeline therapies (5)
  • Eftilagimod alpha (IMP321; Immutep) (5)

Future treatment trends (7)

• Key insights summary (7)

Appendix (6)

• KOL details (6)
  • KOLs from the USA (2)
  • KOLs from Europe (3)